EN
HI
Summary
As of 13 Nov, 2026, Bacil Pharma stock price is ₹16.9. During the trading session, the stock has moved between an intraday low of ₹16.11 and an intraday high of ₹16.99. Over the last 52 weeks, Bacil Pharma has traded between ₹10.65 and ₹61.80.
The stock has recorded a trading volume of 1,603 shares,. Its Average Traded Price (ATP) is ₹16.53, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹16.90.
Bacil Pharma has an upper circuit limit of ₹17.79 and a lower circuit limit of ₹16.11. The total value traded stands at ₹26497.59, and the delivery percentage for the day is 0%.
The stock is currently traded with a market lot size of 1. Bacil Pharma also offers a dividend yield of 0%.
Bacil Pharma Share Price Chart
Bacil Pharma Share Key Metrics
Volume
1603.00
Market Cap
24.39 CR
LTQ@LTP
1@16.90
ATP
16.53
Var Margin
100 %
Circuit Range
16.11-17.79
Delivery %
0 %
Value
26497.59
ASM/GSM
No
Market Lot
1
Bacil Pharma Resistance and Support
Pivot 16.8
Resistance
First Resistance
17.62
Second Resistance
18.29
Third Resistance
19.11
Support
First Support
16.13
Second Support
15.31
Third Support
14.64
Bacil Pharma Historical Data
| Day | Open | Close | Change(%) | Day High | Day Low |
|---|---|---|---|---|---|
| Thu Nov 12 2026 | 16.95 | 16.9 | -0.29% | 16.99 | 16.11 |
| Wed Nov 11 2026 | 17 | 16.95 | 0.83% | 17.46 | 15.97 |
| Mon Nov 09 2026 | 17.07 | 16.81 | -1.35% | 17.37 | 16.19 |
Bacil Pharma Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-14 | Quarterly Results |
| 2026-08-29 | A.G.M. |
| 2026-08-25 | Others |
| 2026-08-12 | Quarterly Results |
| 2026-07-09 | Others |
| 2026-06-26 | Fund Raising & Others |
| 2026-05-22 | Audited Results |
| 2026-02-13 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-09-05 | Others |
| 2025-08-25 | Others |
| 2025-08-12 | Quarterly Results |
| 2025-07-16 | Others |
| 2025-05-26 | Audited Results |
| 2025-01-21 | Quarterly Results |
| 2024-10-23 | Quarterly Results |
| 2024-10-15 | Others |
| 2024-09-27 | Increase in Authorised Capital |
| 2024-08-14 | Quarterly Results |
Bacil Pharma News
Bacil Pharma Ltd - 524516 - Intimation Regarding Execution Of Agreement By Wholly Owned Subsidiary Of The Company
Bacil Pharma's wholly owned subsidiary, Bacil Research and Development, signed an agreement with Efdee Pharma for the R&D of pharmaceutical products. The total estimated project cost is Rs.35 crore.
Nov 04 2026 18:34:59
Bacil Pharma Management
| Name | Position |
|---|---|
| Dinesh Chander Notiyal | Non Executive Independent Director |
| Avani Savjibhai Godhaniya | Non Executive Independent Director |
Bacil Pharma Similar Stocks
Bacil Pharma FAQs
The Buying Price of Bacil Pharma share is 16.9 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Bacil Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Bacil Pharma, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Bacil Pharma shares is 0. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Bacil Pharma shares is 0. Useful to assess the stock's value relative to its book value.
To assess Bacil Pharma’s valuation compare Sector P/E, P/B which are 41.06 & 3.86 with sector averages, along with growth rates and financial metrics.
The Market Cap of Bacil Pharma is 24.39 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Bacil Pharma share price is 61.80 & 10.65. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Bacil Pharma belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year- Auto Square Off Charges
13 Lakh+ Clients
Expert-Backed
Premium Tools
Open Your Free
Demat Account Now!
- AMC For First Year
- Account Opening Fee
- 13 Lakh+ Clients
- Expert-Backed
- Premium Tools
Invest in BACPHAR
